Solifenacin Plus Tamsulosin Combination Treatment in Men With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction: A Randomized Controlled Trial
Kaplan SA, He W, Koltun WD, Cummings J, Schneider T, Fakhoury A. Eur Urol. 2012 Jul 17. [Epub ahead of print]

Source

Weill Medical College of Cornell University, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA.

Abstract

BACKGROUND:

Alpha blockers are prescribed to manage lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Antimuscarinics are prescribed to treat overactive bladder (OAB).

OBJECTIVE:

To investigate the safety of a combination of solifenacin (SOLI) and tamsulosin oral controlled absorption system (TOCAS) in men with LUTS and bladder outlet obstruction (BOO).

DESIGN, SETTING, AND PARTICIPANTS:

Randomized, double-blind, parallel-group, placebo-controlled study in men aged >45 yr with LUTS and BOO for ≥3 mo, total International Prostate Symptom Score (IPSS) ≥8, BOO index ≥20, maximum urinary flow rate (Q(max)) ≤12ml/s, and voided volume ≥120ml.

INTERVENTIONS:

Once-daily coadministration of TOCAS 0.4mg plus SOLI 6mg, TOCAS 0.4mg plus SOLI 9mg, or placebo for 12 wk. OUTCOME

MEASUREMENTS AND STATISTICAL ANALYSIS:

Primary (safety) measurements: Q(max) and detrusor pressure at Q(max) (P(det)Q(max)). Other safety assessments included postvoid residual (PVR) volume. Secondary end points included bladder contractile index (BCI) score and percent bladder voiding efficiency (BVE). An analysis of covariance model compared each TOCAS plus SOLI combination with placebo.

RESULTS AND LIMITATIONS:

Both active treatment groups were noninferior to placebo at end of treatment (EOT) for P(det)Q(max) and Q(max). Mean change from baseline PVR was significantly higher at all time points for TOCAS 0.4mg plus SOLI 6mg, and at weeks 2, 12, and EOT for TOCAS 0.4mg plus SOLI 9mg versus placebo. Both treatment groups were similar to placebo for BCI and BVE. Urinary retention was seen in only one patient receiving TOCAS 0.4mg plus SOLI 6mg. Limitations of the study were that prostate size and prostate-specific antigen level were not measured.

CONCLUSIONS:

TOCAS 0.4mg plus SOLI 6mg or 9mg was noninferior to placebo at EOT for P(det)Q(max) and Q(max) in men with LUTS and BOO, and there was no clinical or statistical evidence of increased risk of urinary retention.